By the Top Tier Newswire AI Desk · July 23, 2026 at 9:37 AM ET · reviewed against 5 wire stories
NOVOCURE LTD (NVCR) is up +27.75% in the latest session. Our newswire has captured 5 stories on NVCR across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Why NVCR stock is up today
NVCR stock surged 27.75% to $19.89 in a volatile session driven by the company's better-than-expected second-quarter results and updated guidance. The stock opened with a 2.4% gap up and reached a high of $20.33 before settling near $19.80. The move reflects investor optimism over Novocure's record net revenue and active patient numbers.
What Happened
Novocure reported Q2 2026 results that exceeded expectations. GAAP earnings per share came in at -$0.13, beating the consensus estimate of -$0.33. Revenue for the quarter reached $183.6 million, a 15.6% year-over-year increase. The company also raised its full-year 2026 sales guidance to a range of $710 million to $725 million, up from the previous range of $690 million to $710 million. The 8-K filing disclosed these results along with updated financial statements. The company highlighted record net revenue and active patient numbers, with margin expansion and global therapy launches reinforcing its progress toward profitability.
What The Data Shows
The stock's intraday session showed significant volatility, with a wide gap up and a high of $20.33 early in the session. Trading volume reached 0.6 million shares, which is 0.4 times the 3-month daily average. The stock's fundamentals remain mixed: it has a market cap of $1.9 billion, unprofitable earnings (TTM EPS -1.54), and revenue growth of 8.5% TTM. The stock has traded between $9.82 and $18.92 over the past 52 weeks. Recent insider transactions include eight sales totaling $940,000 in the last 90 days, with no insider purchases recorded.
What To Watch
The company has already reported its Q2 2026 earnings. Investors should monitor the breadth of coverage and analyst reactions to the updated guidance and financial results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
NVCR · Jul 23 session (5-min) · +28.20% vs prior close · updated 8:54 PM ETAI sentiment, last 36h · averaged over 5 stories · 58/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
6d agoMarketChameleonBULLISH 73Earnings
Novocure's Record Quarter: Patient Growth and Margin Expansion Highlight Positive Momentum
July 23, 2026
Novocure delivered strong Q2 2026 results, achieving record net revenue and active patient numbers. Margin expansion, global therapy launches, and improved financial guidance point to continued progress toward profitability.
6d agoSeeking AlphaBULLISH 68Earnings
NovoCure GAAP EPS of -$0.13 beats by $0.20, revenue of $183.6M beats by $11.16M
NovoCure (NVCR) is scheduled to announce Q2 earnings results on Thursday, July 23rd, before market open. The consensus EPS Estimate is -$0.33 and the consensus
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →